Inactivated rabies vaccine - Liaoning ChengDa Biotechnology

Drug Profile

Inactivated rabies vaccine - Liaoning ChengDa Biotechnology

Alternative Names: Chromatographically purified rabies vaccine - Liaoning ChengDa Biotechnology; Perfusion cell culture based rabies vaccine - Liaoning ChengDa Biotechnology; SPEEDA; TRCS SPEEDA™; Vero cell derived rabies vaccine - Liaoning ChengDa Biotechnology

Latest Information Update: 05 Dec 2014

Price : $50

At a glance

  • Originator Liaoning ChengDa Biotechnology
  • Developer Biovalys; Liaoning ChengDa Biotechnology; Thai Red Cross Society
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 04 Dec 2014 Registered for Rabies (In children, Prevention, In adults) in India, Nepal, Pakistan, Georgia, Belarus, Kenya (Intradermal) before November 2014
  • 04 Dec 2014 Registered for Rabies (In children, Prevention, In adults) in India, Nepal, Pakistan, Georgia, Belarus, Kenya (IM) before November 2014
  • 17 Apr 2013 Launched for Rabies (In children, Prevention, In adults) in Thailand (Intradermal) before April 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top